1. Introduction
===============

Gorgonian corals of the genus *Junceella* (Ellisellidae) are common in subtropical and tropical waters in a number of places around the world, such as the South China Sea and Indo-Pacific Ocean, and are well known as a source of highly oxidized diterpenes of the briarane class (3,8-cyclized cembranoids) \[[@B1-marinedrugs-10-01321]\]. Many *in vitro* and *in vivo* studies on diterpenes isolated from gorgonians showed a variety of biological activities including anti-tumor, anti-inflammatory, antiplasmodial, antibacterial, antiviral, antimalarial and antioxidant, as well as ecologically relevant activities such as fish-feeding deterrence. Diterpenes isolated from gorgonian corals have a large structural diversity with 40 different diterpene classes being represented \[[@B2-marinedrugs-10-01321]\]. Recently, three new 8-hydroxybriarane diterpenoids (junceols A--C) and four new briarane diterpenoids (juncenolides H--K) were reported from a chemical investigation of *Junceella juncea* Pallas collected off the southern Taiwan coast, and some of these metabolites were found to exhibit inhibitory effects on superoxide anion generation and elastase release by human neutrophils \[[@B3-marinedrugs-10-01321],[@B4-marinedrugs-10-01321]\]. Fourteen new briarane diterpenes, juncins O--ZII, were isolated from the EtOH/CH~2~Cl~2~ extract of a South China Sea sample of *J. juncea* and some of them have been shown to exhibit potent antifouling and antifeedant activities \[[@B5-marinedrugs-10-01321],[@B6-marinedrugs-10-01321],[@B7-marinedrugs-10-01321]\]. A bioassay-guided fractionation of the acetone extract of a Taiwanese collection of *J. juncea* led to the identification of seven new diterpenoids, juncenolides A--G \[[@B8-marinedrugs-10-01321],[@B9-marinedrugs-10-01321],[@B10-marinedrugs-10-01321],[@B11-marinedrugs-10-01321]\]. Moreover, a chemical investigation of the Indian Ocean gorgonian *J. juncea* resulted in the isolation of eight new briarane-type diterpenoids, juncins G--N \[[@B12-marinedrugs-10-01321],[@B13-marinedrugs-10-01321],[@B14-marinedrugs-10-01321]\]. A new briarane diterpenoid with antifungal activity was also isolated \[[@B15-marinedrugs-10-01321]\]. In continuation of our research programs oriented towards discovering new metabolites from the gorgonians collected off Taiwanese waters, we reinvestigated *J. juncea*. Examination of different chromatographic fractions of an AcOEt-soluble extract of the Taiwanese *J. juncea* Pallas resulted in the isolation of three new briaranes, designated juncenolides M--O (**1**--**3**) ([Figure 1](#marinedrugs-10-01321-f001){ref-type="fig"}). Their structures were elucidated through detailed spectroscopic analyses, mainly 2D NMR experiments (^1^H, ^1^H COSY, HQMC, HMBC). The relative stereochemistry of the chiral centers and the geometry of the double bonds were deduced from NOESY spectra.

![Structures of compounds **1**--**3**.](marinedrugs-10-01321-g001){#marinedrugs-10-01321-f001}

2. Results and Discussion
=========================

Compound **1** was isolated as a colorless amorphous solid. The molecular formula was determined to be C~28~H~35~ClO~12~ (11 degrees of unsaturation) from the HR-ESI-MS data (*m/z* 621.1711 (\[M + Na\]^+^)), which also showed a M + 2 peak at *m/z* 623.1685 (3:1), indicating the presence of one chlorine atom. Its IR bands revealed the presence of a hydroxyl group (3402 cm^−1^), a five-membered lactone (1779 cm^−1^) and ester groups (1741 cm^−1^). ^1^H- and^13C-NMR\ data^ ([Table 1](#marinedrugs-10-01321-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01321-t002){ref-type="table"}) indicated the presence of four acetates (*δ*~H~ 2.18, s; 2.07, s; 1.97, s; 1.95, s) and *δ*~C~ 170.2 × 2; 170.0 × 2; 21.6; 21.3; 21.0; 20.8, one carbonyl carbon (*δ*~C~ 175.3), and two double bonds (*δ*~C~ 126.1; 128.1; 131.7; 140.0), suggesting four rings in the structure. The protons of CH~2~-20 (*δ*~H~ 3.54, br. s; 2.74, br. *s*), its corresponding carbon (*δ*~C~ 50.2) and the quaternary carbon at *δ*~C~58.1, were assigned to an exocyclic epoxide \[[@B16-marinedrugs-10-01321]\]. The presence of a γ-lactone ring was ascertained by the carbonyl carbon at *δ*~C~ 175.3 (C-18), and the *O*-bearing carbons at *δ*~C~ 78.5 (C-7) and 81.2 (C-8), and confirmed the HMBC correlations ([Figure 2](#marinedrugs-10-01321-f002){ref-type="fig"}) of Me-19/C-8, C-17, C-18 and C-7/C-8, C-18 \[[@B16-marinedrugs-10-01321],[@B17-marinedrugs-10-01321]\]. Four OAc groups were attached to C-2, C-9, C-13 and C-14 by the observation of HMBC correlations ([Figure 2](#marinedrugs-10-01321-f002){ref-type="fig"}). A tertiary methyl signal (*δ*~H~ 1.09, Me-15) correlated with a quaternary carbon (C-1), two oxymethines at *δ*~C~ 74.2 and 73.8, and the CH at *δ*~C~ 41.4, (C-10), implying oxygenation at C-2 and C-14. HMBC correlations of Me-15/C-1, C-2, C-10, C-14, CH~2~-16/C-4, C-5, C-6, CH-7/C-5, C-8, C-18, CH-9/C-8, C-11, and CH-10/C-1, C-8, C-11, C-20, as well as ^1^H--^1^H COSY connectivities between CH-2/CH-3/CH-4, CH-6/CH-7, CH-9/CH-10, CH~2~-12/CH-13/CH-14 ([Figure 1](#marinedrugs-10-01321-f001){ref-type="fig"}), suggested that compound **1** possesses 8-hydroxybriarane-type diterpenoid skeleton together with an exocyclic epoxy group which was corroborated by HMBC correlations of CH~2~-12/C-11, C-20.
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###### 

^1^H NMR Data of Compounds **1**--**3**. *δ* in ppm, *J* in Hz.

  Position   1 ^a^                  2 ^b^                      3 ^b^
  ---------- ---------------------- -------------------------- ----------------------
  2          5.37 (d, *J* = 9.6)    4.94 (overlap)             4.86 (d, *J* = 7.6)
  3          5.62 (t, *J* = 9.6)    1.74--1.78 (m)             2.13--2.16 (m)
                                    2.46--2.50 (m)             2.72 (t, *J* = 10.0)
  4          6.35 (d, *J* = 9.6)    2.19--2.15 (m)             5.91--5.94 (m)
                                    2.64 (br. d, *J* = 13.6)   
  6          6.00 (d, *J* = 9.0)    5.67 (d, *J* = 10.4)       7.06 (d, *J* = 10.0)
  7          4.95 (d, *J* = 9.0)    5.26 (d, *J* = 10.4)       5.62 (d, *J* = 10.0)
  9          4.71 (d, *J* = 4.8)    5.31 (d, *J* = 6.0)        5.56 (d, *J* = 2.8)
  10         3.04 (d,*J* = 4.8)     3.45 (d, *J* = 6.0)        3.25 (d, *J* = 2.8)
  12         1.34--1.38 (m)         2.16--2.19 (m)             2.18--2.23 (2H, m)
             2.48 (d, *J* = 14.0)   2.34--2.36 (m)             
  13         4.96 (overlap)         1.82--1.86 (m)             1.80--1.87 (2H, m)
                                    1.97--1.99 (m)             
  14         5.20 (br. s)           4.59 (br. s)               4.69 (br. s)
  15         1.09 (s)               1.12 (s)                   1.03 (s)
  16         4.58 (2H, s)           2.05 (s)                   \-
  17         2.26 (q, *J* = 6.9)    2.46 (q, *J* = 6.8)        2.63 (q, *J* = 6.8)
  19         1.13 (d, *J* = 6.9)    1.11 (d, *J* = 6.8)        1.19 (d, *J* = 6.8)
  20         2.74 (br. s)           4.92 (s)                   4.95 (s)
             3.54 (br. s)           5.05 (s)                   5.05 (s)
  AcO-2      1.95 (s)               \-                         1.97 (s)
  AcO-4      \-                     \-                         2.06 (s)
  AcO-9      2.18 (s)               2.20 (s)                   2.21 (s)
  AcO-13     2.07 (s)               \-                         \-
  AcO-14     1.97 (s)               1.92 (s)                   1.90 (s)
  OMe-16     \-                     \-                         3.83 (s)

^a^ Recorded in CDCl~3~ at 300 MHz; ^b^ Recorded in CDCl~3~ at 400 MHz.
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###### 

^13^C-NMR Data of Compounds **1**--**3**.*δ* in ppm.

  Position   1 ^a^       2 ^b^       3 ^b^
  ---------- ----------- ----------- -----------
  1          46.5 (s)    46.9 (s)    47.8 (s)
  2          74.2 (d)    75.7 (d)    72.1 (d)
  3          131.7 (d)   31.3 (t)    37.3 (t)
  4          128.1 (d)   29.2 (t)    67.4 (d)
  5          140.0 (s)   144.8 (s)   136.8 (s)
  6          126.1 (d)   120.5 (d)   139.1 (d)
  7          78.5 (d)    77.8 (d)    76.7 (d)
  8          80.8 (s)    83.0 (s)    82.9 (s)
  9          64.3 (d)    71.3 (d)    72.7 (d)
  10         35.7 (d)    41.8 (d)    42.6 (d)
  11         58.1 (s)    150.8 (s)   150.5 (s)
  12         34.3 (t)    26.3 (t)    29.2 (t)
  13         67.7 (d)    26.9 (t)    27.5 (t)
  14         73.8 (d)    74.5 (d)    74.0 (d)
  15         14.4 (q)    15.4 (q)    14.4 (q)
  16         44.7 (t)    27.2 (q)    166.6 (s)
  17         43.9 (d)    42.5 (d)    43.3 (d)
  18         175.3 (s)   175.9 (s)   175.3 (s)
  19         6.3 (q)     6.5 (q)     6.4 (q)
  20         50.2 (t)    113.3 (t)   113.3 (t)
  AcO-2      170.2 (s)   \-          169.9 (s)
             20.8 (q)                20.8 (q)
  AcO-4      \-          \-          169.6 (s)
                                     21.2 (q)
  AcO-9      170.0 (s)   169.3 (s)   169.2 (s)
             21.6 (q)    21.7 (q)    21.7 (q)
  AcO-13     170.0 (s)   \-          \-
             21.3 (q)                
  AcO-14     170.2 (s)   170.4 (s)   170.5 (s)
             21.0 (q)    21.2 (q)    21.1 (q)
  OMe-16     \-          \-          52.8 (q)

^a^ Recorded in CDCl~3~ at 75 MHz; ^b^ Recorded in CDCl~3~ at 100 MHz.

![Key ^1^H--^1^H COSY and HMBC correlations of **1**--**3**.](marinedrugs-10-01321-g002){#marinedrugs-10-01321-f002}

The relative configuration of **1** was determined on the basis of NOESY experiment, MM2 minimized energy calculated molecular modeling ([Figure 3](#marinedrugs-10-01321-f003){ref-type="fig"}), and comparison with other naturally occurring briarane diterpenoids. Briarane-type diterpenoids were previously reported to contain the Me-15 in the β-orientation and H-10 in the α-orientation. As expected, there is no NOE correlation between CH-10 and Me-15. The orientations of CH-10 and the methyl group Me-15 should be opposite. According to MM2 study, we thus concluded that compound **1**had the Me-15 in the β-orientation and CH-10 in the α-orientation as reported \[[@B18-marinedrugs-10-01321]\]. NOESY correlations of CH-10/H-2, CH-9, CH~α~-12, Me-15/CH~2~-20, CH-14, CH~2~-20/CH-13, CH~β~-12 and CH-14/CH-13 suggested the β-orientation of CH-13 and CH-14 and α-orientation of CH-2 and CH-9, a β-oriented exocyclic epoxy group attached to cyclohexane moiety as previously assigned from the ^1^H- and ^13^C NMR data of C-11 and C-20 \[[@B19-marinedrugs-10-01321]\] and the α-orientation of CH-2. The *cis* configuration of the C-3/C-4 double bond was suggested by the NOESY correlations ([Figure 3](#marinedrugs-10-01321-f003){ref-type="fig"}) between CH-3/CH-4 and the *J* value (9.6 Hz). Compound **1** appears to be the chlorinated derivative of juncenolide B isolated from the same species previously \[[@B9-marinedrugs-10-01321]\]. They have the same configuration of chiral centers. Based on the above interpretation, compound **1** is a new chlorinated briarane-type diterpene designated juncenolide M.

![Key NOESY correlations of compounds **1**--**3** in molecular modeling.](marinedrugs-10-01321-g003){#marinedrugs-10-01321-f003}

Compound **2**, isolated as a colorless solid, and had a molecular formula of C~24~H~34~O~8~, deduced from HR-ESI-MS at *m/z* 473.2155 (\[M + Na\]^+^), showing eight degrees of unsaturation. The presence of hydroxyl, a γ-lactone ring, and ester groups were consistent with IR absorptions at 3481, 1772 and 1732 cm^−1^. The ^1^H and^13C\ NMR^ ([Table 1](#marinedrugs-10-01321-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01321-t002){ref-type="table"}), revealed the presence of an exomethylene (*δ*~C~ 150.8, 113.3), one trisubstituted double bond (*δ*~C~ 144.8, 120.5), two OAc carbonyl (C=O) (*δ*~C~ 170.4, 169.3) and one γ-lactone carbonyl (C=O) (*δ*~C~ 175.9), which accounted for five degrees of unsaturation and were suggestive of a tricyclic briarane bearing a γ-lactone ring. The carbonyl signal at *δ*~C~ 175.9 (C-18) was ascribed to a γ-lactone ring with the oxymethine at *δ*~C~ 78.3 (C-7) and the *O*-bearing quaternary carbon at *δ*~C~ 82.2 (C-7). The proton singlets at *δ*~H~ 5.05 and 4.92 (*δ*~C~ 113.3) were assigned to the exocyclic methylene group and correlated to C-10, C-12, and C-11 in the HMBC spectrum ([Figure 2](#marinedrugs-10-01321-f002){ref-type="fig"}), suggesting the presence of a C-11/C-20 double bond. HMBC correlations of Me-15/C-1, C-2, C-14, C-10, Me-16/C-4, C-5, C-6, CH-7/C-5, C-8, C-18, CH-9/C-8, CH-10/C-11, C-1, C8 and the ^1^H, ^1^H COSY correlations of CH-2/CH~2~-3/CH~2~-4, CH-6/CH-7, CH-9/CH-10, CH~2~-12/CH~2~-13/CH-14 revealed the tricyclic skeleton of **2**. Furthermore, two OAc groups positioned at C-9 and C-14 were established by the key correlations observed in the HMBC spectrum of **2.**NOESY experiment revealed that the absence of correlation between and suggested orientation of and disposition of compound **2**. The NOESY correlations ([Figure 3](#marinedrugs-10-01321-f003){ref-type="fig"}) between Me-15/CH-14; CH-10/CH-2, CH-9, CH-9/Me-19, and CH-7/CH-17 were in agreement with the β-orientation of CH-7, CH-14 and CH-17, and α-orientation of CH-2, CH-9 and Me-19. Therefore, compound **2**is a new tricyclic briarane bearing a γ-lactone ring, and was given the name of juncenolide N.

The molecular formula of **3**was established as C~29~H~38~O~13~ from the molecular peak at *m/z* 617.2212 \[M + Na\]^+^ in the HR-ESI-MS. The NMR data ([Table 1](#marinedrugs-10-01321-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01321-t002){ref-type="table"}) revealed the basic features of a 8-hyoxybriarane type diterpenoid with a γ-lactone, one exomethylene double bond, one trisubstituted double bond ([Table 1](#marinedrugs-10-01321-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01321-t002){ref-type="table"}), and four acetate esters. The C-20/C-11 exomethylene double bond was assigned with the aid of HMBC correlations of CH~2~-20/C-10, C-11, C-12. The signal of CH-6 showed correlations to C-4, C-5 and C-16 in HMBC, revealing the C-5/C-6 trisubstituted double bond, and a COOMe group attached to C-5 ([Figure 2](#marinedrugs-10-01321-f002){ref-type="fig"}). The four acetates were deduced to be located at C-2, C-4, C-9, and C-14 by HMBC correlations of the oxymethines at *δ*~H~ 4.86 (CH-2), 5.93 (CH-4), 5.56 (CH-13), and 4.69 (CH-14) to their respective acetate carbonyls. The ^1^H,^1^H COSY connectivities ([Figure 2](#marinedrugs-10-01321-f002){ref-type="fig"}) of CH-2/CH~2~-3/CH-4, CH-6/CH-7, CH-9/CH-10, CH~2~-12/CH~2~-13/CH-14, as well as HMBC correlations of Me-15/C-1, C-2, C-10, C-14, CH-4/C-16, CH-7/C-8, C-18, CH-9/C-8, C-17, CH-10/C-1, C-8, C-11, CH~2~-12/C-11 and Me-19/C-8, C-17, C-18, confirmed the tricyclic skeleton of **3**. The NOESY experiments ([Figure 3](#marinedrugs-10-01321-f003){ref-type="fig"}) showed the relative configuration of compound **3**. Due to the α-orientation of CH-10, the methyl group Me-15 at the ring junction should be β-oriented as no NOE correlation was observed between CH-10 and Me-15. NOESY spectrum clearly displayed the interactions between Me-15/CH-14, CH-10/CH-9, CH-2, CH-2/CH-4, and CH-9/CH-19, indicating that the OAc at C-2, C-4 and C-9 are β-oriented, whereas the OAc at C-14 is in the α-position. Thus, compound **3**is a new briarane ester with a γ-lactone skeleton, and designated juncenolide O.

The isolated briaranes **1**--**3** were tested on inhibitory effects of superoxide anion generation and elastase release by human neutrophils in response to FMLP/CB at a concentration of 10 μg/mL. As illustrated in [Table 3](#marinedrugs-10-01321-t003){ref-type="table"}, compounds **2** and **3** showed moderate inhibitory activities against elastase release with 29.0 ± 5.6%, and 35.9 ± 7.4%, respectively. Furthermore, compound **3** also exhibited moderate inhibitory activity against superoxide anion with 27.6 ± 7.0%.
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###### 

Effects of compounds **1**--**3** on superoxide anion generation and elastase release by human neutrophils in response to FMLP/CB ^a^.

  -------------------- ---------------------- ----------------------
  **Compounds**        **Superoxide anion**   **Elastase release**
  Inhibition (%) ^b^   Inhibition (%)         
  **1**                7.6 ± 2.8              15.9 ± 5.5
  **2**                6.7 ± 2.9              29.0 ± 5.6
  **3**                27.6 ± 7.0             35.9 ± 7.4
  Genistein            65.0 ± 5.7             51.6 ± 5.9
  -------------------- ---------------------- ----------------------

^a^ Results are presented as mean ± S.E.M. (*n* = 3); ^b^ Percent of inhibition at 10 μg/mL.

3. Experimental Section
=======================

3.1. General
------------

Column chromatography (CC); silica gel 60 (Merck, Darmstadt, Germany) and Sephadex LH-20 (Amersham Pharmacia Biotech AB, Uppsala, Sweden). Prep. TLC: pre-coated silica gel plates (Merck; silica gel 60 F-254, 1 mm). LiChrospher Si 60 (5 μm, 250-10, Merck) and LiChrospher 100 RP-18e (5 μm, 250-10, Merck) were used for NP-HPLC and RP-HPLC (Merck, Darmstadt, Germany), respectively. Spray reagent: *p*-anisaldehyde reagent with 5% H~2~SO~4~. Optical rotations: Jasco DIP-1000 polarimeter. UV Spectra: Hitachi U-3210 spectrometer; λ~max~ (log ε) in nm. IR Spectra: Hitachi T-2001 spectrometer; in cm^−1^. ^1^H-, ^13^C-NMR, COSY, HMQC, HMBC, and NOESY experiments: Bruker Avance 300 NMR spectrometer or Varian MR 400 NMR spectrometer, SiMe~4~ as internal standard; *δ* in ppm, coupling constants *J* in Hz. LRESIMS and HRESIMS: JEOL JMS-HX 110 mass spectrometer; in *m/z*.

3.2. Animal Material
--------------------

The gorgonian *Junceella juncea* Pallas (Ellisellidae) was collected in Tai-Tong County, Taiwan, by scuba diving at a depth of 15 m, in November 2006. The fresh gorgonian was immediately frozen after collection and kept at −20 °C until processed. This species was identified by one of the authors (C.-C.L). A voucher specimen (WSG-5) was deposited in the School of Pharmacy, College of Medicine, National Taiwan University, Taiwan.

3.3. Extraction and Isolation
-----------------------------

The outer grey layer of the gorgonian (1.4 kg, wet weight) was extracted with acetone (3 × 500 mL) at r.t., and the acetone extract was concentrated under vacuum. The crude extract (8 g) was partitioned between AcOEt and H~2~O (1:1). The AcOEt-soluble portion (4.9 g) was subjected to column chromatography (SiO~2~, *n*-Hexane/AcOEt 10:1--0:1; TLC (GF~254~) monitoring) giving fractions 1-16. Fr. 12 (195 mg) was subjected to a NP-HPLC (CH~2~Cl~2~/MeOH, 150:1), affording Fr. 12a (12 mg) which was further purified by RP-HPLC (MeOH/H~2~O/CH~3~CN, 70:25:5) yielding compound **1**(6 mg). Fr. 16 (105 mg) was separated by NP-HPLC (CH~2~Cl~2~/MeOH, 80:1), giving Fr. 16a (38 mg) which was subjected to RP-HPLC (MeOH/H~2~O/CH~3~CN, 55:40:5), yielding Fr. 16b (10 mg) that was further purified by RP-HPLC (MeOH/H~2~O/CH~3~CN, 55:40:5) furnishing compounds **2**(4 mg) and **3** (2 mg).

Juncenolide M (**1**): colorless amorphous solid; \[α\]~D~^25^ = −42 (*c* 0.05, CH~2~Cl~2~); UV (MeOH): 221 (3.20); IR (neat): 3402 (OH), 2930, 2853, 1779 (C=O γ-lactone), 1741 (C=O ester) cm^−1^; ^1^H-NMR (300 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-10-01321-t001){ref-type="table"}; ^13^C-NMR (75 MHz, CDCl~3~) data, see [Table 2](#marinedrugs-10-01321-t002){ref-type="table"}; HR-ESI-MS \[M + Na\]^+^ *m/z* 621.1711 (calcd. 621.1715, C~28~H~35~ClO~12~Na).

Juncenolide N (**2**): colorless amorphous solid; \[α\]~D~^25^ = −60 (*c* 0.05, CH~2~Cl~2~); UV (MeOH): 204 (3.90); IR (neat): 3481 (OH), 1772 (C=O γ-lactone), 1732 (C=O ester) cm^−1^; ^1^H-NMR (400 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-10-01321-t001){ref-type="table"}; ^13^C-NMR (100 MHz, CDCl~3~) data, see [Table 2](#marinedrugs-10-01321-t002){ref-type="table"}; HR-ESI-MS \[M + Na\]^+^ *m/z* 473.2155 (calcd. 473.2151, C~24~H~34~O~8~Na).

Juncenolide O (**3**): colorless amorphous solid; \[α\]~D~^25^ = +4 (*c* 0.05, CH~2~Cl~2~); UV (MeOH): 220 (3.80), 205 (3.90); IR (neat): 3423 (OH), 3020, 2921, 2850, 1780 (C=O γ-lactone), 1738 (C=O ester) cm^−1^; ^1^H-NMR (400 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-10-01321-t001){ref-type="table"}; ^13^C-NMR (100 MHz, CDCl~3~) data, see [Table 2](#marinedrugs-10-01321-t002){ref-type="table"}; HR-ESI-MS \[M + Na\]^+^ *m/z* 617.2212 (calcd. 617.2210, C~29~H~38~O~13~Na).

3.4. Anti-Inflammatory Assays
-----------------------------

Neutrophils were obtained by means of dextran sedimentation and Ficoll centrifugation. Superoxide generation and elastase release were carried out according to a procedure described previously \[[@B20-marinedrugs-10-01321]\]. Superoxide anion production was assayed by monitoring the superoxide dismutase-inhibitable reduction of ferricytochrome *c*. Elastase release experiments were performed using MeO-Suc-Ala-Ala-Pro-Valp-nitroanilide as the elastase substrate. Genistein was used as a positive control.

4. Conclusions
==============

Three new diterpenoids, named juncenolides M--O (**1**--**3**), were isolated from the Taiwanese gorgonian *Junceella juncea* Pallas. Compound **1** is a new chlorinated briarane, compound **2** is a new brierane with a free hydroxy at C-2, while compound **3** contains a rare methyl ester at C-5. The anti-inflammatory activities tested on superoxide anion generation and elastase release by human neutrophils in response to FMLP/CB were evaluated. As a result, compounds **2** and **3** showed moderate inhibitory activities against elastase release at 10 μg/mL.
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